Wockhardt Ltd (WOCKPHARMA) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Wockhardt Ltd reported a strong operational performance with revenue of INR 3033 crores and EBITDA of INR 418 crores.
- EBITDA grew by 67% and the EBITDA margin expanded by 500 basis points to 14%.
- Biosimilar business experienced a 20% growth.
- Net debt-to-equity ratio significantly reduced to 0.01%, with a total debt reduction to INR 326 crores, aided by a QIP of INR 1000 crores.
- The company is transitioning from a generics focus to a research-driven model, with novel antibiotics and biotechnology contributing 18% of sales.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.